Whitworth, Hilary

Whitworth, Hilary

Affiliate Board member

Assistant Professor, Clinical Research Department, London School of Hygiene and Tropical Medicine (LSHTM), London, UK

Hilary Whitworth (PhD) is an Assistant Professor in the Clinical Research Department at LSHTM, with an MSc in Epidemiology and a PhD in immunology. She has worked in infectious disease research for 12 years; for the past 8 years, her research has been based in Sub-Saharan Africa.

One of Dr Whitworth’s primary research areas of interest is HPV infection and HPV vaccination. She is a co-investigator of the ongoing DoRIS trial, which is comparing the safety and immunogenicity of 1 vs 2 or 3 doses of 2 different HPV vaccines in Tanzanian schoolgirls. Dr Whitworth is also a member of the PATH-convened Single-Dose HPV Vaccine Evaluation Consortium, which aims to collate and evaluate data from clinical trials, observational studies and modeling analyses regarding the value of single-dose HPV vaccination for protection against cervical cancer. Results from the DoRIS trial and the work of the Single-Dose HPV Vaccine Evaluation Consortium contributed to the evidence base supporting the World Health Organization’s recent change in recommendations that allow for 1-dose or 2-dose HPV vaccination up to 20 years of age.

Dr Whitworth’s research continues to have a key focus on generating evidence to support strategies and policies that will contribute to cervical cancer elimination. She is a co-investigator of a Tanzania-based cluster randomised trial (the ‘Add-Vacc’ trial) that is evaluating the population-level impact of a novel gender-neutral HPV vaccination strategy, offering one-time single-dose HPV vaccine to boys alongside the existing national HPV vaccination programme in girls. She is also the LSHTM co-lead of a newly-formed multi-partner collaboration, led by the International Vaccine Institute, that aims to increase our understanding of the burden and epidemiology of HPV infection in eight countries across Sub-Saharan Africa and South Asia to inform decision-making on strategies to reduce HPV transmission and prevent cervical cancer in these areas.